AbCellera Biologics Is Up 124% Even As Sales Fell

If you only glanced at AbCellera Biologics’ headlines over the year, the picture looked mixed. Q2 2026 revenue was lower than the prior year and losses deepened, even as fresh trial updates and partnerships grabbed attention. Investors who held AbCellera Biologics over the past year are up 123.8%, including dividends. If you had been deciding on 21 October 2025, would those early clinical ambitions have outweighed the earnings risk?

The easy part of this move is behind AbCellera Biologics. Zero in on 33 high quality undervalued stocks for companies trading below our estimates.

The Two Stories Investors Had To Weigh On AbCellera Biologics

The shares cost US$5.58 at the start of the period, so any view on AbCellera Biologics needed to start with whether that price made sense against its early clinical plans.

The bullish Narrative argued that Phase I trials for ABCL635 and ABCL575 plus new manufacturing capacity could reshape the business. It pointed to a Fair Value of US$9.22, a price implied by optimistic assumptions, with a key belief that integrated clinical manufacturing would improve efficiency and margins once fully in use.

The bearish Narrative still saw upside but questioned how much. It anchored on a Fair Value of US$5, again an implied price from its own model, and focused on the risk that revenue would stay volatile because it depended heavily on uncertain clinical milestones and royalty streams.

What The Evidence Did To The AbCellera Biologics Debate

The key development after October 2025 was ABCL635 moving from early data to Phase 2 with positive efficacy in menopausal vasomotor symptoms, which supported the bullish focus on internal programs and manufacturing. At the same time, Q2 2026 revenue fell to US$4.05 million from US$17.084 million and the net loss widened to US$55.427 million from US$34.727 million. Taken together, the evidence cut both ways.

The lesson is simple. When a story leans on a pipeline, treat each trial milestone and each quarter’s revenue and loss as separate tests of the same claim, and track whether progress in the lab is matched by improving income statements elsewhere.

What AbCellera Biologics' Run Already Assumes

Today AbCellera Biologics trades at US$12.24, with this Narrative’s Fair Value framed as sitting below that quote. The argument hinges less on past gains and more on how quickly the business can turn an R&D heavy model into meaningful product revenue.

A buyer at today’s price is effectively betting ABCL635 grows into a large nonhormonal option, so the selected Narrative asks how trial duration, safety, adoption and funding risks intersect with that expectation.

"The main thing that has to go right is for ABCL635 to convert its early clinical profile in vasomotor symptoms into successful Phase III data, regulatory approval and meaningful uptake in the large nonhormonal treatment market. The current valuation implies investors are already paying up for AbCellera Biologics as if ABCL635 secures sizeable share in multibillion dollar vasomotor symptom markets and T-cell engager partnerships eventually deliver substantial milestone and royalty income."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Looking Beyond AbCellera's Pipeline

AbCellera Biologics highlights early science and potential antibody therapies. You could also examine a business already selling widely used medicines.

Weight management and diabetes treatments now influence how healthcare budgets get allocated. One large pharmaceutical group has focused its recent efforts on injectables for those conditions.

It also has late stage programs seeking to expand its obesity and metabolic footprint. Another drug in pill form aims at patients who avoid injections entirely.

This shift, from injections alone to a mix including tablets, widens treatment choices. That different route could matter alongside AbCellera Biologics’ work on new antibodies.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 16% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com